Prosecution Insights
Last updated: April 19, 2026

Takeda Pharmaceuticals U S A Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17998085 METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY WHITEMAN, BRIAN A 1636 Non-Final OA Nov 07, 2022
17299186 METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY MEYERING, SHABANA SHABBEER 1635 Final Rejection Jun 02, 2021
17299275 METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY MCKILLOP, JOHN CHARLES 1637 Non-Final OA Jun 02, 2021

Managing Takeda Pharmaceuticals U S A Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month